Medicine and Dentistry
Ovarian Cancer
100%
Olaparib
75%
Overall Survival
55%
Bevacizumab
54%
Low Risk Population
50%
Fetus Monitoring
50%
Echography
50%
Group Process
50%
Prenatal Care
50%
Cesarean Section
50%
Uterine Cancer
50%
Progression Free Survival
34%
Sentinel Lymph Node
25%
Attitude
25%
Tumor Cell
25%
Oncology
25%
Proctopexy
25%
Integrative Medicine
25%
Pelvic Floor Dysfunction
25%
Radical Hysterectomy
25%
Cervical Cancer
25%
Prematurity
25%
Breech Extraction
25%
Surgery
25%
Embryo Quality
25%
Volumetry
25%
Gestational Sac
25%
First Trimester Pregnancy
25%
Birth
25%
Axillary Surgery
25%
Pediatrics
25%
Transgender
25%
Shoulder Dystocia
25%
Trial of Labor
25%
Electron Intraoperative Radiotherapy
25%
Triglyceride-Glucose Index
25%
Recurrent Disease
23%
Homologous Recombination
23%
Cord Blood
21%
Blood pH
21%
Hysterectomy
21%
Hazard Ratio
20%
Supine Position
20%
Diagnosis
19%
Gynecology
17%
Base Excess
17%
Pelvis
17%
Placebo
14%
Arm
13%
PARP Inhibitor
13%
Blastomere
12%
Adolescent Medicine
12%
Health Care
12%
Obstetric Medicine
12%
Health Promotion
12%
Adolescence
12%
Instrumental Delivery
12%
Pelvic Floor
10%
Obstetrics
10%
Gender Identity
10%
Reproductive Medicine
10%
Differential Scanning Calorimetry
10%
Umbilical Artery
10%
Newborn Morbidity
10%
Disease Exacerbation
9%
Intrapartum
9%
Survival Rate
8%
Lymph Duct
7%
Recurrence Free Survival
7%
Birth Weight
7%
Neonatal Intensive Care Unit
7%
Postoperative Complication
7%
Urine Incontinence
7%
Clinical Research
7%
Blighted Ovum
7%
Gestational Age
7%
Enuresis
7%
Lymphatic Tissue
7%
Post-Hoc Analysis
6%
Vaginal Ultrasonography
6%
Embryo Cell
6%
BRCA2
6%
Oocyte Retrieval
6%
Pregnancy Rate
6%
Embryo Transfer
6%
Spontaneous Abortion
6%
Single Embryo Transfer
6%
Antibiotic Prophylaxis
6%
Neoplasm
5%
Adjuvant Therapy
5%
Chemotherapy
5%
Vaginal Delivery
5%
Fetus Distress
5%
Quadrantectomy
5%
3D Computed Tomography
5%
Labor Stage 2
5%
Obstetric Intervention
5%
Pharmacology, Toxicology and Pharmaceutical Science
Olaparib
75%
Ovary Cancer
75%
Bevacizumab
54%
Overall Survival
50%
Progression Free Survival
34%
Breast Cancer
25%
Alpha Amino 3 Hydroxy 5 Methyl 4 Isoxazolepropionic Acid
25%
Glutamate Receptor
25%
Melatonin
25%
Uterine Cervix Cancer
25%
Recurrent Disease
25%
Endocrine Therapy
25%
Antibiotic Prophylaxis
25%
Chemotherapy
19%
Placebo
14%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
13%
Urine Incontinence
12%
Formaldehyde
12%
Enuresis
12%
Side Effect
10%
Disease Exacerbation
9%
Neoplasm
8%
Survival Rate
8%
Epidermal Growth Factor Receptor 2
6%
Gamma Urogastrone
6%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
6%
Malignant Neoplasm
6%
Urine Retention
6%
Alzheimer's Disease
6%
Noninferiority Trial
6%
Mouse Model
6%
Cancer Recurrence
6%
Disease Course
6%
Clinical Trial
5%
Cardiovascular Disease
5%